Monopar Therapeutics withholds 597 CEO shares for tax
The post-transaction position includes 104,127 directly held shares and 62,815 shares held indirectly by the Chandler D. Robinson Irrevocable Trust.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) reports that CEO and director Chandler Robinson had 597 common shares withheld by the issuer on October 20, 2026, to pay applicable withholding tax. The additional withholding was due to an administrative error in connection with the vesting and settlement of 12,873 restricted stock units on June 30, 2026. Robinson’s reported direct holdings after the transaction were 104,127 shares. The Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020, was separately reported as holding 62,815 shares indirectly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock F1 | 597 | $92.59 | $55K |
| holding | Common Stock F2 | -- | -- | -- |
Footnotes (2)
- F1. Represents additional shares withheld by the issuer to pay for the applicable withholding tax due to administrative error in connection with the vesting and settlement of 12,873 restricted stock units on June 30, 2026, as reported on a Form 4 filed July 2, 2026.
- F2. Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
Key Figures
Key Terms
restricted stock units financial
withholding tax financial
vesting and settlement financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.